Morphic Holding Inc. is planning an IPO of its common stock on the Nasdaq Global Market.

The Waltham, Mass.-based biopharmaceutical company is focused on developing oral integrin therapies, with its early experimental drugs aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis.

Morphic plans to list its common stock on the Nasdaq Global Market under the symbol MORF.

The company plans to use the proceeds from the offering to fund further development of its experimental drugs and use any remaining amounts to fund working capital and general corporate purposes.

Jefferies LLC, Cowen and Co. LLC, BMO Capital Markets Corp. and Wells Fargo Securities LLC are listed as underwriters for the IPO.